Skip to main content
OpenTrials
Completed

NCT Number: NCT02125474

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Well-differentiated neuroendocrine tumors (WDNETs) are uncommon neoplasms with an increasing number of new cases reported in the annual statistics of the Instituto Nacional de Cancerología (INC). The majority are advanced-stage presentations with limited chances of a complete surgical resection of the primary tumor, a clinical scenario where medical treatment options are also limited. In view of the characteristically defined expression of peptide receptors in WDNETs, radioactive molecular probes to target specific cellular receptors have been designed using radioisotopes with short range of penetration in tissues. We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET. Selected patients matching inclusion criteria will be enrolled at the INC's Section of Endocrinology. Tumor response, treatment safety (side effects) and survival will be appraised. Data from clinical, biochemical and imaging follow-up will be periodically registered during treatment and until two years after the last infusion of 177Lu- DOTATATE. This phase II trial is justified because despite the fact that many preclinical and clinical studies have showed the potential usefulness of this novel palliative approach to treat patients with advanced-stage WDNETs there is a paucity of vigorous results to establish its efficacy as first-line treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuroendocrine Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Instituto Nacional de Cancerología

Bogota, Cundinamarca, 00000, Colombia

About this study

The Investigators have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with inoperable gastroenteropancreatic neuroendocrine tumors.
  • Histopathologic diagnosis confirmed at the Instituto Nacional de Cancerología.
  • Somatostatin receptor-positive tumors with at least one site of abnormal focal uptake > liver physiologic uptake (3+) observed in a 99mTc-HYNIC-TOC scintigraphy practiced less than 6 months before treatment with 177Lu- DOTATATE.
  • Karnofsky functional score > 60.
  • Life expectancy > 3 months.
  • Multiple inoperable metastatic sites.
  • Patient voluntarily willing to participate in the trial.
  • Hemoglobin (Hb) > 8.8 g/dl
  • Leucocytes (Leu) > 2 x 103/µl
  • Platelets (Plaq) > 80 x 103/µl
  • Total Bilirrubin (BT) ≤ 3 times the upper limit of normal range. Serum albumin > 3 g/dl and normal prothrombin time.
  • At least one measurable CT tumor lesion.
  • Non-lactating woman with negative pregnancy blood test.
  • Creatinine clearance > 40 ml/min and serum creatinine < 1.5 mg/dl and/or isotopic glomerular filtration rate > 50 ml/min.
  • Test results should predate treatment by at least: blood test results ≤ 4 weeks, liver blood tests < 1 month, renal function tests < 1 week, CT ≤ 4 months and 99mTc-HYNIC-TOC scintigraphy < 6 months.

Exclusion criteria

  • Patients previously treated with radionuclide therapy.
  • Patients treated with chemo- o radiotherapy within the past 6 months.
  • Patients unable to comply with clinical follow-up in both Nuclear Medicine and Endocrinology units.
  • Patients unwilling to participate in the trial or not providing written informed consent.

Treatment and study plan

[177Lu] DOTA-TATE

Radiation

We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.

Primary outcomes

  1. Response to treatment

    Time frame: 3 years

    Response to palliative treatment with 177Lu- DOTATATE in patients with metastatic progressive low-grade neuroendocrine tumors defined by control size tumor, response time to reduction minimal parcial and complete tumor.

Secondary outcomes

  1. Efficacy defined by reduction in size tumoral

    Time frame: 3 years

    Measure the efficacy of 177Lu- DOTATATE to treat patients with metastatic progressive low-grade neuroendocrine tumors using clinical and imaging criteria such as tumor size.

  2. Side effects defined by clinical follow up

    Time frame: 5 years

    Describe the side effects of the treatment with 177Lu- DOTATATE by clinical follow-up during and after therapy

  3. survival rate

    Time frame: 2 years

    describe the 2-year survival rate of patients treated with 177Lu- DOTATATE

  4. Quality of life

    Time frame: 3 years

    Assess the quality of life of patients with metastatic progressive low-grade neuroendocrine tumors treated with 177Lu- DOTATATE during treatment defined by pain reduction and tolerability.

Sponsors and collaborators

Lead sponsor

Instituto Nacional de Cancerologia, Columbia

Other Gov

Registry information

Official study title

Efficacy of Peptide Receptor Radionuclide Therapy for Metastatic Inoperable Neuroendocrine Tumors Using 177-Lu-DOTA 0, Tyr 3 Octreotate

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Apr 29, 2014
Registry last updated
Nov 14, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.